These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1321908)

  • 41. 4-[5-Fluoro-3-[4-(2-methyl-1H-imidazol-1-yl)benzyloxy]phenyl]-3,4,5,6- tetrahydro-2H-pyran-4-carboxamide, an orally active inhibitor of 5-lipoxygenase with improved pharmacokinetic and toxicology characteristics.
    Mano T; Okumura Y; Sakakibara M; Okumura T; Tamura T; Miyamoto K; Stevens RW
    J Med Chem; 2004 Jan; 47(3):720-5. PubMed ID: 14736252
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacological cross-reactivity between 5-lipoxygenase-activating protein, 5-lipoxygenase, and leukotriene C4 synthase.
    Gupta N; Nicholson DW; Ford-Hutchinson AW
    Can J Physiol Pharmacol; 1997; 75(10-11):1212-9. PubMed ID: 9431445
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor.
    Li L; Ji H; Sheng L; Zhang Y; Lai Y; Chen X
    Eur J Pharmacol; 2009 Apr; 607(1-3):244-50. PubMed ID: 19243697
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Criteria for the identification of non-redox inhibitors of 5-lipoxygenase.
    Falgueyret JP; Hutchinson JH; Riendeau D
    Biochem Pharmacol; 1993 Feb; 45(4):978-81. PubMed ID: 8452572
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation.
    Lorrain DS; Bain G; Correa LD; Chapman C; Broadhead AR; Santini AM; Prodanovich PP; Darlington JV; Stock NS; Zunic J; King CD; Lee C; Baccei CS; Stearns B; Roppe J; Hutchinson JH; Prasit P; Evans JF
    Eur J Pharmacol; 2010 Aug; 640(1-3):211-8. PubMed ID: 20519143
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies.
    Kachur JF; Askonas LJ; Villani-Price D; Ghoreishi-Haack N; Won-Kim S; Liang CD; Russell MA; Smith WG
    J Pharmacol Exp Ther; 2002 Feb; 300(2):583-7. PubMed ID: 11805220
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of leukotriene C4 and B4 release by human eosinophils with the new 5-lipoxygenase inhibitor 6-hydroxy-2(4-sulfamoylbenzylamino)-4,5,7-trimethylbenzothiazo le hydrochloride.
    Fukuda T; Numao T; Akutsu I; Toda M; Motojima S; Makino S
    Arzneimittelforschung; 1995 Sep; 45(9):1002-4. PubMed ID: 7488299
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation.
    Nickerson-Nutter CL; Medvedeff ED
    Arthritis Rheum; 1996 Mar; 39(3):515-21. PubMed ID: 8607901
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition by methylprednisolone of zymosan-induced leukotriene synthesis in alveolar macrophages.
    Peters-Golden M; Thebert P
    Am Rev Respir Dis; 1987 May; 135(5):1020-6. PubMed ID: 3034108
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of antigen-induced contraction of guinea-pig airways by a leukotriene synthesis inhibitor, BAY x1005.
    Gardiner PJ; Cuthbert NJ; Francis HP; Fitzgerald MF; Thompson AM; Carpenter TG; Patel UP; Newton BB; Mohrs K; Müller-Peddinghaus R
    Eur J Pharmacol; 1994 Jun; 258(1-2):95-102. PubMed ID: 7925604
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010.
    Hamel P; Riendeau D; Brideau C; Chan CC; Desmarais S; Delorme D; Dubé D; Ducharme Y; Ethier D; Grimm E; Falgueyret JP; Guay J; Jones TR; Kwong E; McAuliffe M; McFarlane CS; Piechuta H; Roumi M; Tagari P; Young RN; Girard Y
    J Med Chem; 1997 Aug; 40(18):2866-75. PubMed ID: 9288168
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Benzothiazole hydroxy ureas as inhibitors of 5-lipoxygenase: use of the hydroxyurea moiety as a replacement for hydroxamic acid.
    Greco MN; Hageman WE; Powell ET; Tighe JJ; Persico FJ
    J Med Chem; 1992 Aug; 35(17):3180-3. PubMed ID: 1324317
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor with potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model.
    Horizoe T; Nagakura N; Chiba K; Shirota H; Shinoda M; Kobayashi N; Numata H; Okamoto Y; Kobayashi S
    Inflamm Res; 1998 Oct; 47(10):375-83. PubMed ID: 9831321
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics and pharmacodynamics of fenleuton, a 5-lipoxygenase inhibitor, in ponies.
    Marr K; Marsh K; Hernandez L; Cunningham FM; Lees P
    Res Vet Sci; 1998; 64(2):111-7. PubMed ID: 9625466
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of 5-lipoxygenase inhibitors, zileuton, A-78773 and ICI-D-2138 in an ionophore (A-23187)-induced pleural inflammation model in the rat.
    Rao TS; Currie JL; Shaffer AF; Isakson PC
    Life Sci; 1993; 53(9):PL147-52. PubMed ID: 8394967
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.
    Bell RL; Bouska JB; Malo PE; Lanni C; Harris RR; Otis ER; Stewart AO; Brooks DW; Carter GW
    J Pharmacol Exp Ther; 1995 Feb; 272(2):724-31. PubMed ID: 7853186
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds.
    Hatzelmann A; Fruchtmann R; Mohrs KH; Raddatz S; Müller-Peddinghaus R
    Biochem Pharmacol; 1993 Jan; 45(1):101-11. PubMed ID: 8381000
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543.
    Showell HJ; Conklyn MJ; Alpert R; Hingorani GP; Wright KF; Smith MA; Stam E; Salter ED; Scampoli DN; Meltzer S; Reiter LA; Koch K; Piscopio AD; Cortina SR; Lopez-Anaya A; Pettipher ER; Milici AJ; Griffiths RJ
    J Pharmacol Exp Ther; 1998 Jun; 285(3):946-54. PubMed ID: 9618393
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prostaglandins inhibit 5-lipoxygenase-activating protein expression and leukotriene B4 production from dendritic cells via an IL-10-dependent mechanism.
    Harizi H; Juzan M; Moreau JF; Gualde N
    J Immunol; 2003 Jan; 170(1):139-46. PubMed ID: 12496393
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization and pharmacological modulation of antigen-induced peritonitis in actively sensitized mice.
    Zuany-Amorim C; Leduc D; Vargaftig BB; Pretolani M
    Br J Pharmacol; 1993 Oct; 110(2):917-24. PubMed ID: 7694762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.